$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000165731223000011 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.44M	$9.590M	$7.440M
YoY Change	125.12%	28.9%	-19.83%
% of Gross Profit
Research & Development	$1.120M	$12.61M	$17.63M
YoY Change	-92.52%	-28.45%	29.84%
% of Gross Profit
Depreciation & Amortization	$157.0K	$157.0K	$163.0K
YoY Change	-4.85%	-3.68%	6.54%
% of Gross Profit
Operating Expenses	$9.965M	$22.20M	$25.07M
YoY Change	-51.41%	-11.43%	9.66%
Operating Profit	-$9.965M	-$22.20M	-$25.07M
YoY Change	-51.41%	-11.43%	9.66%
Interest Expense	$740.0K	$293.0K	$84.00K
YoY Change	713.19%	248.81%	0.0%
% of Operating Profit
Other Income/Expense, Net	$1.468M	$5.629M	$310.0K
YoY Change	-47.96%	1715.81%	-81.17%
Pretax Income	-$8.497M	-$16.57M	-$24.76M
YoY Change	-51.96%	-33.06%	16.71%
Income Tax	$310.0K	$173.0K	$82.00K
% Of Pretax Income
Net Earnings	-$8.807M	-$16.74M	-$24.84M
YoY Change	-50.43%	-32.59%	16.66%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01	-$0.03	-$0.05
Diluted Earnings Per Share	-$0.01	-$0.03	-$0.05
COMMON SHARES
Basic Shares Outstanding	635.7M shares	631.9M shares	481.9M shares
Diluted Shares Outstanding	634.5M shares	621.5M shares	481.9M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$270.7M	$291.4M	$132.8M
YoY Change	142.78%	119.5%	-21.72%
Cash & Equivalents	$270.7M	$291.4M	$132.8M
Short-Term Investments
Other Short-Term Assets	$6.060M	$2.073M	$2.525M
YoY Change	174.71%	-17.9%	70.15%
Inventory
Prepaid Expenses	$894.0K	$1.561M	$1.246M
Receivables
Other Receivables
Total Short-Term Assets	$287.8M	$306.9M	$153.0M
YoY Change	107.62%	100.64%	-18.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.00K	$12.00K	$71.00K
YoY Change	-87.91%	-83.1%	-27.55%
Goodwill	$545.0K	$545.0K	$545.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M	$15.00M
YoY Change	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$16.10M	$16.26M	$16.36M
YoY Change	-0.78%	-0.64%	956.17%
TOTAL ASSETS
Total Short-Term Assets	$287.8M	$306.9M	$153.0M
Total Long-Term Assets	$16.10M	$16.26M	$16.36M
Total Assets	$303.9M	$323.1M	$169.3M
YoY Change	96.27%	90.85%	-10.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.493M	$7.237M	$8.064M
YoY Change	-73.38%	-10.26%	1390.57%
Accrued Expenses	$7.467M	$17.70M	$28.88M
YoY Change	-73.89%	-38.7%	239.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.95M	$26.52M	$37.90M
YoY Change	-71.83%	-30.02%	198.5%
LONG-TERM LIABILITIES
Long-Term Debt	$19.86M	$19.81M	$4.900M
YoY Change	297.14%	304.27%	4.26%
Other Long-Term Liabilities	$30.00K	$65.00K	$177.0K
YoY Change	-77.27%	-63.28%	-55.75%
Total Long-Term Liabilities	$19.89M	$19.87M	$5.105M
YoY Change	288.95%	289.3%	1.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.95M	$26.52M	$37.90M
Total Long-Term Liabilities	$19.89M	$19.87M	$5.105M
Total Liabilities	$30.84M	$46.40M	$43.01M
YoY Change	-29.88%	7.88%	142.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$359.1M	-$350.1M	-$288.7M
YoY Change	17.09%	21.27%	26.4%
Common Stock	$41.75M	$41.75M	$32.18M
YoY Change	29.74%	29.74%	1.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$975.0K	$1.208M	$739.0K
YoY Change	64.97%	63.46%	-55.75%
Treasury Stock Shares
Shareholders Equity	$273.1M	$276.7M	$126.3M
YoY Change
Total Liabilities & Shareholders Equity	$303.9M	$323.1M	$169.3M
YoY Change	96.27%	90.85%	-10.96%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$8.807M	-$16.74M	-$24.84M
YoY Change	-50.43%	-32.59%	16.66%
Depreciation, Depletion And Amortization	$157.0K	$157.0K	$163.0K
YoY Change	-4.85%	-3.68%	6.54%
Cash From Operating Activities	-$21.31M	-$5.782M	-$14.51M
YoY Change	9.19%	-60.16%	-21.77%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$67.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	124.0K	$68.69M	-$726.0K
YoY Change	-118.0%	-9560.74%
NET CHANGE
Cash From Operating Activities	-21.31M	-$5.782M	-$14.51M
Cash From Investing Activities	0.000	$0.00	$0.00
Cash From Financing Activities	124.0K	$68.69M	-$726.0K
Net Change In Cash	-21.19M	$63.59M	-$15.62M
YoY Change	4.7%	-507.2%	-15.08%
FREE CASH FLOW
Cash From Operating Activities	-$21.31M	-$5.782M	-$14.51M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$21.31M	-$5.782M	-$14.51M
YoY Change	9.35%	-60.16%	-21.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38067
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
CY2023Q1	dei	Entity Address Country EntityAddressCountry	GB
CY2023Q1	dei	Country Region CountryRegion	44
CY2023Q1	dei	City Area Code CityAreaCode	203
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	283 4200
CY2023Q1	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
CY2023Q1	dei	Trading Symbol TradingSymbol	VRNA
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	635667302	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291415000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227827000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1561000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2499000	usd
CY2023Q1	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	11842000	usd
CY2022Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	9282000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2073000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3388000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	306891000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	242996000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	545000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	698000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	854000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	16255000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16472000	usd
CY2023Q1	us-gaap	Assets Assets	323146000	usd
CY2022Q4	us-gaap	Assets Assets	259468000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7237000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2910000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17703000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13752000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	650000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	675000	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	424000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	283000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	509000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1409000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	26523000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19029000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19809000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9768000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	65000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	205000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	19874000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9973000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	46397000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	29002000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	651659630	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631338246	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	631987078	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	606301054	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	41753000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40526000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	590915000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	529187000	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1208000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1549000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-350110000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333097000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	276749000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	323146000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259468000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12610000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17625000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9589000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7440000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	22199000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	25065000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22199000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25065000	usd
CY2023Q1	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	2313000	usd
CY2022Q1	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1302000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	2677000	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	15000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	293000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	84000	usd
CY2023Q1	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	932000	usd
CY2022Q1	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-923000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5629000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	310000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16570000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24755000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	173000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	82000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16743000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	621451000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	621451000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	481942000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	481942000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16743000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56909000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1827000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4290000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	276749000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	usd
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	793000	usd
CY2022Q1	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	-118000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3747000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	126307000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16743000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	932000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1119000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	73000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	23000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	18000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	31000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4290000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3748000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	157000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	163000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-938000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2791000	usd
CY2023Q1	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	2313000	usd
CY2022Q1	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	1578000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1362000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	462000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4327000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1980000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3951000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6621000	usd
CY2023Q1	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-165000	usd
CY2022Q1	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-174000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	141000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	88000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-886000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-65000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5782000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14512000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56862000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9996000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	793000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1827000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68685000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-726000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	685000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-378000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	63588000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15616000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291415000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132764000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	244000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	53000	usd
CY2023Q1	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-350100000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company’s estimates.</span></div>
CY2023Q1	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	15127000	usd
CY2022Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	12314000	usd
CY2023Q1	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	1775000	usd
CY2022Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	1364000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	801000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	74000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17703000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13752000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4290000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3748000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19276496	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1320000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	240000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1050192	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19306304	shares
CY2023Q1	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16743000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	621451000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	621451000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	481942000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	481942000	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	49500000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	60600000	shares
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	6900000	usd

Files In Submission

Name	View Source	Status
vrna-20230331_lab.xml	Edgar Link	unprocessable
vrna-20230331_pre.xml	Edgar Link	unprocessable
vrna-20230331_cal.xml	Edgar Link	unprocessable
0001657312-23-000011-index-headers.html	Edgar Link	pending
0001657312-23-000011-index.html	Edgar Link	pending
0001657312-23-000011.txt	Edgar Link	pending
0001657312-23-000011-xbrl.zip	Edgar Link	pending
exhibit311q123.htm	Edgar Link	pending
exhibit312q123.htm	Edgar Link	pending
exhibit321q123.htm	Edgar Link	pending
exhibit322q123.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20230331.htm	Edgar Link	pending
vrna-20230331.xsd	Edgar Link	pending
vrna-20230331_g1.jpg	Edgar Link	pending
vrna-20230331_def.xml	Edgar Link	unprocessable
vrna-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2023 Q2 Form 10-Q Financial Statement

#000165731223000011 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2023 Q2 Form 10-Q Financial Statement

#000165731223000011 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna